Kintor Pharma Gets Mega-Booster from Experimental Covid-19 Drug

Company posted major milestone last week with the first emergency use authorization for its drug Proxalutamide to treat the coronavirus in Paraguay Key points:  Kintor Pharma’s Proxalutamide could become a blockbuster drug if it receives emergency use approval in the U.S. as a treatment for Covid-19 The company’s stock has jumped sevenfold this year, outpacing even the most bullish analyst targets By Alice Leung It’s relatively rare to see a stock trade higher than analysts’ targets, since such people tend to be quite bullish on the companies they follow. But…

Read MORE »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read MORE »

Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI

Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential Inclusion typically represents validation for a company’s products and outlook By Richard Barbarossa Drug and healthcare R&D firms are well-represented in the latest round of additions to the MSCI China All Shares Index, highlighting the sector’s growth potential and strong fundamentals. Some new ascendants to the list are even…

Read MORE »

Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should continue to surge on new product approvals and inclusion of a core product on the National Reimbursement Drug List Company’s losses could continue to balloon as it pursues expensive new licensing deals at the cost of near-term profits By Richard Barbarossa Cancer and autoimmune drug specialist Zai Lab Ltd.(Nasdaq: ZLAB; 9688.HK) is poised to accelerate approval of new medicines and…

Read MORE »

CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped CStone post its first-ever significant revenues and narrowing losses in 2020 The company is eying new approvals for more uses of its cancer drugs as big-name global pharma companies pump it up with cash By Richard Barbarossa CStone Pharmaceuticals Co. Ltd (2616.HK), a Chinese maker of immuno-oncology therapies and precision medicines, is moving closer to profitability after its losses narrowed…

Read MORE »

Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own

Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology and immunology business will more than triple on new approvals and more direct control over its sales and marketing Stiff competition in cancer drugs and divestiture of its profitable but non-core OTC business could result in continued net losses By Richard Barbarossa Hutchison China MediTech Ltd. (Nasdaq: HCM; HCM.L), a leading Chinese maker of cancer drugs backed by Hong Kong…

Read MORE »

Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part

Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key takeaways: Henlius is one of the earliest entrants to China’s young biosimilar market, giving it a first-mover advantage The company will need to quickly develop more new drugs, boost production and sign new partnerships to stay ahead in an increasingly crowded field By Richard Barbarossa Biosimilar specialist Shanghai Henlius Biotech, Inc. (HKEx: 2696) is set to ramp up production after…

Read MORE »